Institution Directory

Clinical trials at Memorial Sloan Kettering Cancer Center

Sites in New York, NY

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 1:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1675

Shown on this page

Current sort

Live official records

Conditions: Refractory Acute Lymphoblastic Leukemia, Relapsed Acute Lymphoblastic Leukemia
Interventions: Venetoclax, Navitoclax, Dexamethasone, Vincristine, Calaspargase Pegol, Dasatinib, Cytarabine, Blinatumomab, Methotrexate, Mercaptopurine, Cyclophosphamide, Etoposide, Leucovorin, Intrathecal Triples, Pegaspargase, Erwinia asparaginase, Radiation; Drug · Biological · Radiation
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 4 Years to 30 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 2
States / cities: New York, New York • Memphis, Tennessee

Conditions: Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma, Muscle Invasive Ureter Urothelial Carcinoma, Muscle Invasive Urethral Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma AJCC v6 and v7, Stage III Bladder Urothelial Carcinoma AJCC v6 and v7, Stage IV Bladder Urothelial Carcinoma AJCC v7
Interventions: Biospecimen Collection, cfDNA or ctDNA Measurement, Computed Tomography, Cystoscopy, Magnetic Resonance Imaging, Nivolumab, Questionnaire Administration, Relatlimab; Procedure · Other · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 992 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 492
States / cities: Phoenix, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 372 more

Conditions: Cognitive/Functional Effects, Psychosocial Effects of Cancer and Its Treatment, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: questionnaire administration, cognitive assessment, psychosocial assessment and care; Other · Procedure
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 65 Years to 120 Years
Enrollment: 1,062 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2027
U.S. locations: 8
States / cities: Beverly Hills, California • Duarte, California • Orange, California + 5 more

Conditions: Essential Thrombocythemia
Interventions: INCA033989, Best Available Treatment; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 426 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 42
States / cities: Birmingham, Alabama • Gilbert, Arizona • Duarte, California + 35 more

Conditions: Locally Recurrent Skin Squamous Cell Carcinoma, Metastatic Skin Squamous Cell Carcinoma
Interventions: Amivantamab and Recombinant Human Hyaluronidase, Biospecimen Collection, Cetuximab, Computed Tomography, Magnetic Resonance Imaging; Drug · Procedure · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 55
States / cities: Birmingham, Alabama • Gilbert, Arizona • La Jolla, California + 48 more

Conditions: Recurrent Glioma, Recurrent WHO Grade 2 Glioma, Recurrent WHO Grade 3 Glioma, Recurrent WHO Grade 4 Glioma
Interventions: Biospecimen Collection, Erdafitinib, Magnetic Resonance Imaging, Optical Coherence Tomography; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 27
States / cities: Aurora, Colorado • Coral Gables, Florida • Deerfield Beach, Florida + 19 more

Conditions: Advanced Endometrial Carcinoma, Recurrent Endometrial Carcinoma
Interventions: Bevacizumab, Biospecimen Collection, Carboplatin, Computed Tomography, Magnetic Resonance Imaging, Paclitaxel, Pembrolizumab; Biological · Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 303
States / cities: Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 226 more

Conditions: Advanced Solid Tumors
Interventions: GS-2426; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 5
States / cities: Boston, Massachusetts • Grand Rapids, Michigan • East Brunswick, New Jersey + 2 more

Conditions: Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
Interventions: zolbetuximab, nab-paclitaxel, gemcitabine; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 393 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 25
States / cities: Fullerton, California • Whittier, California • Meriden, Connecticut + 22 more

Conditions: Multiple Myeloma, Amyloidosis
Interventions: Melphalan, Pegfilgrastim, Autologous Hematopoietic Progenitor Cell Transplant; Device · Drug · Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Acute Myeloid Leukemia
Interventions: Azacitidine, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Gilteritinib, Venetoclax; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 225
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 179 more

Conditions: Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancers, Esophageal Squamous Cell Carcinoma, Triple Negative Breast Cancer, Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer, Head and Neck Squamous-Cell Carcinoma, Platinum Resistant High Grade Epithelial Ovarian Cancer
Interventions: ABBV-400, Itraconazole (ITZ), Bevacizumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 20
States / cities: Duarte, California • San Francisco, California • Aurora, Colorado + 15 more

About this Memorial Sloan Kettering Cancer Center institution page

What this page lists: ClinicalTrials.gov records that list Memorial Sloan Kettering Cancer Center in New York, NY as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Memorial Sloan Kettering Cancer Center

Filter and sort this campus

Live official records

Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

Assessment Tool for Older Patients With Cancer

A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia

Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System

Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

Study of GS-2426 in Participants With Advanced Solid Tumors

A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer

Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant.

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

About this Memorial Sloan Kettering Cancer Center institution page